1. Celecoxib vs diclofenac sodium in patients with knee osteoarthritis
- Author
-
Chen Hongyun, Jianke Pan, Weiyi Yang, Lingfeng Zeng, Guihong Liang, Jun Liu, Biqi Pan, and Hetao Huang
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,medicine.diagnostic_test ,Visual analogue scale ,business.industry ,MEDLINE ,General Medicine ,Diclofenac Sodium ,Osteoarthritis ,medicine.disease ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,030220 oncology & carcinogenesis ,Erythrocyte sedimentation rate ,Internal medicine ,Meta-analysis ,medicine ,Celecoxib ,030212 general & internal medicine ,business ,medicine.drug - Abstract
Background Knee osteoarthritis (KOA) is one of the most common chronic muscular diseases in old people. The purpose of this meta-analysis was to compare celecoxib and diclofenac sodium in patients with knee osteoarthritis (KOA). Methods Randomized controlled trials (RCTs) and clinical controlled trials (CCTs) comparing the use of celecoxib and diclofenac sodium in KOA patients were retrieved from each database from the date of database inception to September 2019. The outcome measurements were the treatment effect, visual analog scale (VAS) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and complication rate. The pooled data were evaluated with Review Manager 5.3.5. Results The literature will provide a high-quality analysis of the current evidence supporting celecoxib for KOA based on various comprehensive assessments including the treatment effect, visual analog scale (VAS) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and complication rate. Conclusion This proposed systematic review will provide up-to-date evidence to assess the effect of celecoxib in the treatment for patients with KOA. RESEARCH REGISTRY REGISTRATION NUMBER:: reviewregistry827.
- Published
- 2020
- Full Text
- View/download PDF